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BACKGROUND: Chronic Obstructive Pulmonary Disease is one of the leading causes of 
morbidity and mortality in the United States. With early detection, COPD is a treatable disease, 
highlighting the need for an effective screening measure. The COPD Population Screener 
Questionnaire (COPD-PS) is a valid, accurate questionnaire that can identify individuals likely to 
have COPD.  
PURPOSE: The purpose of this study was to evaluate the impact of a provider-based educational 
intervention on the knowledge, attitudes, self-efficacy and screening rates of COPD using the 
COPD-PS screening tool among primary care providers. 
METHODS: This study was a single-center, pre/post implementation study to evaluate provider 
screening rates for COPD, provider knowledge, attitudes and self-efficacy regarding COPD 
screening and utilization of the COPD-PS screening tool. Phase one of the study was a baseline 
chart review and provider pre-implementation survey. Phase two was a provider educational 
intervention covering COPD and COPD-PS screening tool. Third phase study was a post-
implementation chart review and provider post-implementation survey.  
RESULTS: There was an increase in overall means from the baseline to the posttest scores, but 
these changes were not statistically significant: provider knowledge (pre=6.75, post=7.00, 
p=.391), attitude (pre=4.12, post=4.93, p=.090), or self-efficacy (pre=4.12, post=5.00, p=.133). 
There was a statistically significant increase in provider practice for COPD screening using 
surveys (p=.003), performing COPD-PS screening tool (p=.001), documentation of COPD-PS 
(p=.001) and spirometry ordered (p=.001) from the pre- to post-intervention period. 
CONCLUSION: Utilization of a questionnaire-based screening tool, such as the COPD-PS can 
increase COPD screening rates and identify at risk patients who may benefit from diagnostic 
spirometry.  
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Chronic obstructive pulmonary disease (COPD) is a common, preventable and 
progressive respiratory condition limiting an individual’s ability to breathe (Global Initiative for 
Chronic Obstructive Lung Disease (GOLD), 2019). COPD is a leading cause of morbidity and 
mortality in the United States and is projected to be the third leading cause of death globally by 
2020 (GOLD, 2019). In 2014, an estimated 13.7 million individuals in the United States were 
diagnosed with COPD and an additional 24 million were undiagnosed or misdiagnosed (CDC, 
2018). The slow progression of COPD means that its early symptoms are often unrecognized by 
both patients and providers despite having significant clinical deterioration in health status, 
quality of life and increased risk of morbidity and mortality (Yawn, et al., 2014). The hallmark 
symptoms of COPD are exertional dyspnea, increased sputum production, and chronic cough 
(GOLD, 2019). Numerous risk factors are associated with a diagnosis of COPD, however 
exposure to cigarette smoke and other noxious particles are the best studied risk factors for 
COPD (GOLD, 2019). COPD not only affects individual health but it has become a financial 
burden for the healthcare system. Healthcare expenditures due to hospital admissions and co-
morbidities associated with COPD alone are estimated at 50 billion dollars (Schwab, et al., 
2017). Without addressing early screening for COPD in at risk individuals, an increased number 
of individuals will have a missed diagnosis of COPD, resulting in no treatment while the disease 
progresses and worsens a patient’s quality of life and overall health status.  
Early detection of COPD in the primary care setting through screening at risk individuals 
can improve short-and long-term patient outcomes, increase quality of life, decrease co-
morbidities, mortality, and reduce costs related to underdiagnosed COPD (Schwab, et al., 2017). 
Recent studies have found that one out of every three adults age 40 years and older who are 
diagnosed as having asthma actually have COPD and one in five adults age 40 years and older 
who smoke have undiagnosed COPD (Anzueto, Heijdra, & Hurst, 2015). Primary care providers 
play a pivotal role in early recognition of COPD by recommending diagnostic testing based on 
screening eligible patients. However, early screening may not be performed on a regular basis in 
the primary care setting due to lack of provider knowledge about available screening tools for 
COPD. Awareness of COPD screening needs to be heightened in both patients and providers, as 
poor knowledge and expertise are significant barriers to diagnosis of COPD (Weiss et al., 2014). 
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While spirometry remains the gold standard for detecting and quantifying airflow 
obstruction in COPD, it is not feasible or cost-effective for routine screening in the primary care 
setting (Johns, Walters, & Walters, 2014). Therefore, it is important to determine feasible, cost-
effective ways of evaluation patients at risk for airflow obstruction.  The COPD Population 
Screener Questionnaire (COPD-PS) is a tool recommended as an evidence-based solution to 
assist in early diagnosis and diagnostic testing for COPD in at risk patients by primary care 
providers (Martinez, et al., 2008). Patients that receive a positive score of five or higher on the 
COPD-PS screening tool are advised to have spirometry performed to confirm a diagnosis of 
COPD (COPD Foundation, 2019; Martinez, et al., 2008).  
 The purpose of this project was to determine the effectiveness of a provider-based 
educational intervention on the knowledge, attitude, self-efficacy, and screening rates of COPD 
using the COPD-PS screening tool among primary care providers in one primary care office. 
Background 
COPD is the fourth most common cause of mortality and disability in the US, with higher 
incidences in Kentucky than the majority of other states (Croft, et al., 2018). As of 2017, for 
every 100,000 people, 62.8 people have died from COPD in Kentucky, making Kentucky the 
state with the highest rates of deaths related to COPD (CDC, 2018). COPD is a significant 
independent risk factor for deaths related to other causes such as lung cancer, diabetes and heart 
disease (Anzueto, Heijdra, & Hurst, 2015).  In Kentucky, there are estimates of diagnostic rates 
of COPD at 11.3% compared to the overall national average of 6.3% with prevalence of COPD 
significantly higher among women (13.3%) compared to men (9.4%) (KyBRBS, 2016). In 
addition, COPD rates are projected to continue rising, as the population continues to age. It is 
estimated that 1.1 billion people in the world smoke, resulting in an estimated 328 million people 
who are diagnosed with COPD (Anzueto, Heijdra, & Hurst, 2015). Along with increased 
smoking rates and an aging population, the forecasted increase in COPD is projected to become a 
worldwide problem by 2020 (CDC, 2017). The incidence of emergency department visits due to 
COPD complications is 5.6%, however this number could be higher (CDC, 2017), since 63% of 
adults with evidence of impaired lung function have never been diagnosed with a lung disease 
(Han, et al., 2015). Therefore, it is essential to screen at risk patients for COPD in order to 
accurately diagnose patients in the early phase of the disease when more treatment options are 
available for better patient outcomes. 
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Screening Recommendations  
 The United States Preventive Services Task Force (USPSTF) recommends against 
routine screening for COPD in asymptomatic adults. This recommendation, however, applies 
only to asymptomatic adults who do not report respiratory symptoms such as chronic cough, 
sputum productions, dyspnea or wheezing to their primary care provider (USPSTF, 2017). The 
American College of Physicians (ACP), American College of Chest Physicians (ACCP), 
American Thoracic Society (ATS), and European Respiratory Society (ERS) recommend that 
spirometry should be obtained to diagnose airflow obstruction in patients with respiratory 
symptoms (Grade: strong recommendation, moderate-quality evidence) and spirometry should 
not be used to screen for airflow obstruction in individuals without respiratory symptoms (Grade: 
strong recommendation, moderate-quality evidence) (Qaseem, et al., 2011). The USPSTF has 
identified 3 externally validated questionnaires based on risk factors, symptoms, or both: They 
are: the COPD Diagnostic Questionnaire, the Lung Function Questionnaire, and the COPD 
Population Screener (COPD-PS; 2017). Utilizing a COPD questionnaire is a feasible method to 
identify symptomatic patients at risk of COPD who could benefit from diagnostic spirometry 
(Yawn, et al., 2014). In addition, the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines recommend considering a diagnosis of COPD and perform spirometry, if any 
of the following indicators are present in an individual over age 40: 1.) dyspnea: that is 
progressive over time, characteristically worse with exercise or persistent; 2.) chronic cough: that 
may be intermittent and may be unproductive; 3.) recurrent wheeze; 4.) chronic sputum 
production; 5.) recurrent lower respiratory tract infections; 6.) history of  risk/host factors such as 
(genetic factors, congenital/developmental abnormalities), tobacco smoke, smoke from home 
cooking and heating fuels and occupational dusts, vapors, fumes, gases and other chemicals; and, 
7.) family history of COPD and/or childhood respiratory infections. Patients that meet screening 
requirements are to be referred to spirometry to confirm COPD diagnosis (GOLD, 2019).  
Screening Tools 
 GOLD guidelines recommend using the mMRC (Modified Medical Research Council) 
Dyspnea Scale, The COPD Control Questionnaire (The CCQ) and the COPD Assessment Test 
(CAT) to quantify the impact of COPD symptoms on patients’ overall health, guide treatment 
interventions in patients already diagnosed with COPD and predict future mortality risk (GOLD, 
2019; Perez, et al., 2015). Although GOLD guidelines recommend the use of mMRC, the CCQ 
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and CAT are recommended for measuring the progression of COPD once it has been diagnosed. 
However, none of these instruments have specifically attempted to identify previously 
undiagnosed individuals with clinically significant COPD or who are at high risk of developing 
COPD (Han, et al., 2015). Therefore, utilization of a screening questionnaire, such as the COPD-
PS in undiagnosed, symptomatic patients in the primary care setting could aid in diagnosis of 
COPD. 
COPD-PS 
The COPD Population Screener Questionnaire (COPD-PS) is a first-line screening tool 
recommended as an evidenced-based solution to aid in early diagnosis and diagnostic testing of 
COPD in at risk patients by primary care providers (Martinez, et al., 2008). The COPD-PS was 
developed by five pulmonologists, four primary care physicians and one respiratory therapy 
professor. The tool was developed to facilitate communication between healthcare providers and 
patients about their respiratory symptoms with their healthcare providers. The COPD-PS is a 
simple, self-administered and self-scored five-item questionnaire that measures the presence, 
frequency, duration, or quality of symptoms by asking 5 questions related to: a) dyspnea; b) 
cough; c) functional impact; d) smoking; and e) age. Patients that meet screening requirements 
for COPD-PS and receive a score of five or higher should be referred for diagnostic spirometry 
to confirm a diagnosis of COPD (COPD Foundation, 2019).  See Appendix A for COPD-PS 
Screen questionnaire 
Review of Literature 
Screening using the COPD-PS has been shown to be effective as an alternative approach 
to early and accurate diagnosis of COPD in the primary care setting due to the simplicity of 
questions that can cross a range of all literacy levels in the general population (Martinex, et al., 
2008; Spyratos, Haidich, Chloros, Michaelopoulou, & Sichletidis, 2017; Tsukuya, et al., 2015; 
Yawn, et al., 2014). Screening using the COPD-PS tool has also been shown to increase 
motivational levels to quit smoking among patients who identify as current smokers (Kaplan & 
Thomas, 2017). 
The COPD-PS screening tool is highly sensitive and specific for diagnosis of COPD 
following spirometry confirmation (Duvall & Frank, 2010; Martinez, et al., 2008; Spyratos, 
Haidich, Chloros, Michaelopoulou, & Sichletidis, 2017;). For instance, a COPD-PS score cut 
point of 5 or more out of a possible 10, predicted COPD with a sensitivity of 84.4% and 
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specificity of 60.7% (Martinez, et al., 2008), while Tsukuya, et al’s., study resulted in a 
sensitivity of 67.1% and specificity of 72.9% (2015).  
  Individuals with higher COPD-PS scores are more likely to have increased airway 
obstruction, which is associated with a diagnosis of COPD (Martinez, et al., 2008; Spyratos, 
Haidich, Chloros, Michaelopoulou, & Sichletidis, 2017 & Tsukuya, et al., 2015). Martinez, et al, 
found that out of 295 patients with a positive (score of 5 or higher) COPD-PS screen who 
underwent spirometry, approximately 38% had COPD based on their spirometry results (2008). 
Likewise, Spyratos, Haidich, Chloros, Michaelopoulou, & Sichletidis (2017) found that out of 
351 patients 10.9% had COPD based on spirometry results (2017).  
The COPD-PS has been found to have a high positive predictive value (PPV) on 
accurately diagnosing COPD compared to other screening tools and is applicable to all primary 
care settings (Martinez, et al., 2008; Spyratos, Haidich, Chloros, Michaelopoulou, & Sichletidis, 
2017). Furthermore, Martinez, et al’s., (2008) results of a 68.4% PPV aligned with  results from 
Spyratos, Haidich, Chloros, Michaelopoulou, & Sichletidis’s, (2017) who found a 41% PPV in 
accurately diagnosing COPD with utilization of the COPD-PS tool. Previous studies have shown 
that the COPD-PS screening tool has a high negative predictive value ranging from 96% 
(Spyratos, Haidich, Chloros, Michaelopoulou, & Sichletidis (2017) to 97% (Tsukuya, et al., 
(2015), indicating that those who did not have a positive COPD-PS are truly not at risk for 
COPD. 
Screening programs and ongoing education for providers to use simple screening tools, 
such as the COPD-PS among high-risk populations in primary care is a feasible way to reduce 
the percentage of underdiagnosed COPD (Martinez, et al., 2008; Spyratos, Haidich, Chloros, 
Michaelopoulou, & Sichletidis, 2017 & Tsukuya, et al., 2015). Furthermore, the 5-item COPD-
PS screening tool that is based on presenting risk factors, signs and symptoms (Martinez, et al., 
2008) is inexpensive and takes approximately 3-5 minutes for the healthcare provider to review 
results for further recommendations. Dissemination of this screening tool can assist providers in 
identifying patients who would need spirometric assessment to diagnose COPD. Implementation 
of the COPD-PS in the primary care setting is essential for early diagnosis and treatment of 
individuals at risk for development of COPD.  
 
 




 Transformational Learning Theory by Mezirow guided the education intervention for 
providers in this project to teach primary care providers new knowledge and skills related to 
screening for COPD. The theory of transformational learning in adults is that new learning is 
actually created and circumscribed by a previous frame of reference, from an individual’s 
previous point of view, which influences their new thinking, beliefs and actions (Hoggan, 2016). 
Transformational learning education involves challenging current beliefs and thought patterns on 
an existing topic, in order to awaken the learner to a new way of viewing and examining a 
problem or way of thinking (Mezirow, 1981). As healthcare continues to change, a provider’s 
ability to learn new material in order to improve patient care is necessary, even if their current 
knowledge, beliefs and attitudes about a topic differ from the one being taught. Transformational 
learning theory was appropriate to use for this study because it focuses on changing and 
challenging providers’ knowledge and attitudes about a topic for which they have a  bias or 
strong opinions about  (i.e., screening is not necessary for COPD). During the educational 
session providers were given the task of using the COPD-PS to screen at risk patients for COPD. 
Providers that chose to participate in the study used critical reflection to try a new method of 
primary prevention that was previously not used in their everyday practice.  
Transformative learning facilitated providers to critically reflect on the validity of new 
evidence given to them during the educational session. Provider participation in the study 
demonstrates the provider’s agreement to learning new knowledge and skills, which diverges 
from their current practice of performing patient care. Accomplishment of integrating this theory 
into this project is evident by provider participation, positive COPD-PS screening forms and 
increased rates of referral for spirometry testing.  
Purpose 
The purpose of this project was to evaluate the effect of a provider-based educational 
intervention on primary care providers’ (a) knowledge of COPD screening and use of COPD-PS 
screening tool; (b) attitudes about screening for COPD and using COPD-PS; (c) self-efficacy of 
screening for COPD using COPD-PS screening tool (d) screening rates of COPD in at risk 
patients and (e) identify barriers and facilitators to screening. 
 
 





This study was based on a single center quasi-experimental pre-posttest design to assess 
provider screening rates for COPD, knowledge, attitudes and self-efficacy on screening for 
COPD and using the COPD-PS screening tool before and after an educational intervention. The 
study took place in three phases. Phase one of the study consisted of a pre-implementation chart 
review and a provider pre-implementation survey. Phase two of the study consisted of an 
educational intervention for providers. Finally, phase three consisted of a post-implementation 
chart review and post-implementation provider survey. 
Setting 
The study took place at one primary care office in Louisville Kentucky. This office 
primarily serves residents of the metropolitan area and Southern Indiana for comprehensive 
services, including preventive medicine, screening, wellness exams, care for chronic conditions, 
and acute medical visits. Approximately 200 patients with ages across the lifespan are seen each 
day in this office.   
Sample 
Providers 
Provider inclusion criteria for this study sample included primary care providers 
(physicians and nurse practitioners) who attended the educational intervention and completed the 
pre-implementation survey on June 1, 2019. Exclusion criteria involved providers who did not 
attend the educational meeting and complete the pre-implementation survey.  
This practice setting consisted of a total of ten providers, with two female and four male 
physicians and four female nurse practitioners. To recruit provider participation, flyers were 
posted around the office to inform providers of the survey and the upcoming educational session. 
Next, emails were sent to providers two weeks before the educational session to remind 
providers to take the survey prior to educational session. The email detailed the purpose of the 
study, as well as the risk and benefits for participating in the study.  
Patients 
Patients included in the study were from the primary care office that served as the study 
site. A total of 100 medical records were randomly selected by the data analysts within the 
healthcare system  during the pre-intervention phase from patients who were seen in office prior 
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to the intervention between June 1, 2018 and August 31, 2018 who met the study inclusion 
criteria. Inclusion criteria were: patients seen by a provider who attended the educational 
intervention, patients male or female, age 40 years or older, current or history of smoking in their 
chart who present to the office with complaints of at least one of these variables: cough, dyspnea, 
shortness of breath or had a history of a lower respiratory tract infection and an ICD 10 code of 
at least one of the following, R05 (cough), R06.00 (dyspnea), R06.09 (other forms of dyspnea), 
R06.0 (dyspnea), R06.02 (shortness of breath), J22 (unspecified acute lower respiratory tract 
infection), F17 (nicotine dependence), F17.210 (nicotine dependence, cigarettes) and Z87.891 
(personal history of nicotine dependence). Another 100 medical records were randomly selected 
from patients who were seen in office after the intervention between June 1, 2019 and August 31, 
2019 who met the study inclusion criteria, which was identical from the pre-intervention 
inclusion criteria. Exclusion criteria for both the pre-post chart review included: patients less 
than forty years of age, current diagnosis of COPD or ICD code J44.9 in patients’ medical chart, 
pregnant at time of the healthcare visit and provider did not attend the educational intervention. 
The research office at the healthcare system  provided a report of patient medial record numbers  
based on patients who met the study inclusion criteria for the single site setting. A password 
protected electronic crosswalk table was assembled to simplify the data collection process. 
Institutional Review Board Approval 
The project received approval under the UK IRB, entitled The Effect of Provider 
Education on COPD Screening Rates in the Primary Care Setting (IRB#46940 ID#10440532). 
Study Procedures 
 This study consisted of three phases.  
Phase One: Consisted of a pre-implementation chart review and provider pre-
implementation survey  
Part 1: Part one of phase one consisted of a provider pre-implementation chart review to 
assess baseline screening for patients at risk for COPD using the COPD-PS screening tool and 
number of referrals for spirometry. This chart review took place from June 1, 2018 to August 31, 
2018, and 100 randomly selected charts were reviewed to assess provider screening rates for 
COPD that met screening qualifications. An approved waiver of documentation of informed 
consent was obtained for this study.   
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Patients were asked to read a consent letter form, which described the purpose, potential 
risks and benefits of participating in the study. Patients that agreed to participate in the study 
filled out the screening form. Patients were informed that their information would be used only 
for this study and that the information they provided was secure and confidential.   
Part 2: Part two of phase one consisted of a provider pre-implementation survey that was 
distributed via email using Qualtrics. The providers who participated and completed the survey 
were assigned a unique identifier to maintain anonymity. The pre-implementation survey was 
used to assess provider knowledge, attitude and self-efficacy of screening for COPD, as well as 
providers perceived barriers for screening and utilization of the COPD-PS screening tool (see 
Appendix B Survey Instrument Pre-Post Test). Providers that completed the pre-implementation 
survey, voluntarily consented to participate in the study. (see Appendix C for Provider Email 
Consent).  
Phase Two: Consisted of an educational intervention for providers. 
Phase two consisted of an educational intervention for providers that took place June 1, 
2019. The intervention consisted of provider education about identifying patients at risk for 
COPD, implementation and documentation of the COPD-PS screening tool, as well as the next 
steps after a positive COPD-PS score. The educational intervention took place for 15 minutes 
during the monthly provider staff meeting. Copies of the COPD-PS screening tool and copies of 
patient consent forms that patients would review and sign for the study were provided and issued 
during the meeting for provider reference. Providers were educated on the screening tool and 
providers were asked to discuss where to document the screening tool after completion. During 
the meeting, all providers agreed to have nursing scan a copy of the screening tool into the Media 
tab on the patients electronic medical record( EMR)  and for providers to document the score in 
the patient’s chart. Since there is no current screening tool or tab in Epic for COPD, providers 
were asked for their preference for documenting and recording the tool. Scoring of the screening 
tool was discussed with the providers. Providers were educated that patients who met screening 
criteria and scored a 5 or great on the COPD-PS screening tool, warranted a referral for 
diagnostic spirometry. Providers were aware that they would need to place a referral for 
outpatient screening since there is currently no spirometry screening offered in the office. No 
incentive was rewarded for the providers who voluntarily participated in the study. Screening 
forms, hats and pins for patients who completed the screening tool were donated by the COPD 
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Foundation. Patients of providers that voluntarily agreed to participate in the study and who met 
the inclusion criteria for COPD screening were given an in-person COPD-PS screening form and 
were asked to complete the COPD-PS form during their office visit.  
Patients 
First, a patient survey cover letter was given to each patient prior to filling out the 
screening form. The survey cover letter described the study as well as the risks and benefits of 
participation.  Then screening forms were given to patients that agreed to participate in the study. 
Patient completion of the COPD-PS screening form was used as a waiver of informed consent. 
(see Appendix D for Patient Survey Cover Letter). Patients that completed a screening form were 
offered a COPD hat or pen for participating in the study.  
Providers 
Nursing staff provided the cover letter and screening tool for patients to read and fill out. 
Nurses scanned the patient’s completed COPD-PS in the media section in the patient’s EMR and 
distributed a hat or pin to patients that participate in the study. Prior to starting the patient visit, 
nursing staff notified providers of both a positive and negative score. Provider’s then discussed 
results with patients, and if a positive score was found, placed an outpatient referral for 
diagnostic spirometry. Patients were educated that they did not have to go for spirometry but that 
it was advised to confirm a diagnosis of COPD.   
Phase 3: Consisted of a post-implementation chart review and post-implementation 
provider survey  
Part 1: Consisted of a post-implementation chart review to assess the number of patients 
being screened for COPD using the COPD-PS screening tool and number of referrals for 
spirometry. A post-implementation chart review was performed during the months of June to 
August 2019, using 100 randomly selected charts for patients who met the screening criteria. 
Screening criteria was the same as in part one phase one of the study. Screening rates for COPD 
and referrals for spirometry were compared to the findings in part one phase one, to determine if 
an educational intervention increased screening rates and diagnosis of COPD. A waiver of 
documentation of informed consent was requested and approved. 
Part 2: Consisted of a post-implementation provider survey via email using Qualtrics. 
Providers who completed the pre-implementation survey were the same providers who were 
asked to complete the post-implementation survey. The post-implementation survey was the 
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same as the pre-implementation survey that was used to assess provider knowledge, attitude and 
self-efficacy of screening for COPD, as well as providers perceived barriers for screening and 
utilization of the COPD-PS screening tool. Results of the survey for pre and post-data were 
evaluated by the unique identifier, and not the participant's name or email address. Findings of 
the post-implementation survey were compared to the pre-implementation survey to determine if 
provider knowledge, attitude, self-efficacy and screening rates increased after an educational 
intervention. (see Appendix B Survey Instrument Pre-Post Test).   
Measures 
A survey of knowledge, attitudes, self-efficacy and assessing barriers and facilitators of 
screening for COPD using the COPD-PS was created by the PI based on the GOLD guidelines 
and COPD Foundation COPD-PS screening tool (see Appendices A and B). The pre-
implementation survey was distributed to the providers’ emails for completion prior to the June 
educational meeting. The post-implementation survey was distributed during the last week of the  
intervention in August 2019. The survey was the same for both the pre- and post-test. The survey 
included seven multiple choice questions to test provider knowledge, eight Likert-style questions 
to assess their attitudes and self-efficacy, three questions to assess current screening practice, and 
two fill-in answer questions to assess barriers and facilitators related screening for COPD and 
use of the COPD-PS screening tool. 
To assess provider screening for COPD using the COPD-PS screening tool, 
documentation of the screening tool and referral rates for spirometry, 100 randomly selected 
charts of patients seen in the office from the months of June-August 2018, and 100 randomly-
selected charts of patients seen after the intervention from the months of June-August 2019 were 
selected, using the sample inclusion and exclusion criteria. The results were stored in a Microsoft 
Excel spreadsheet. See Table 1 for summary of variables.  
Data Analysis 
Statistical analysis was completed using IBM SPSS statistical software version 26. 
Descriptive statistical analysis using frequencies and means were used to describe the sample 
and a chi-square test was used to compare findings in the pre/post-implementation groups. 
Differences between variables in the samples before and after the intervention were assessed 
using chi-square analysis to assess patient age, gender, ethnicity, patient reported symptoms, 
ICD-10 codes in EHR, COPD-PS performed on eligible patients and documentation of COPD-
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PS screening tool. Variances in the proportion of spirometry ordering rates before and after the 
intervention were assessed using chi-square analysis. Differences between variables in the 
samples before and after the intervention were assessed using paired sample t-tests to assess 
changes in provider knowledge, attitudes and self-efficacy. Provider’s perception on barriers and 
facilitators in COPD screening in the primary care were described qualitatively.  
Results 
 The study sample included 170 patients aged 40-62+ and four primary care providers 
from one primary care office setting. Appendix tables 2, 3, 4 and 5 demonstrate the detailed 
results from the study. 
Provider 
Of the ten primary care providers, only six primary care providers were in attendance at 
the meeting and four providers voluntarily participated in the study and completed both the pre- 
and post-test (67% participation rate). The identity of those four providers is anonymous. The 
ratio of male to female providers was even, with two physicians and two nurse practitioners and 
all providers had five or more years of experience. See Table 2 for provider demographics.  
Patients  
The primary investigator performed a chart review of 200 randomly selected patients who 
met all inclusion criteria and for whom screening was indicated during the pre-and-post 
intervention time frame. Of those 200 randomly selected patient charts, 30 patients were 
excluded in the post-intervention study because of a diagnosis of COPD in their chart, leaving a 
total sample of 170 patients. Of those 170 randomly selected charts, 100 charts were from pre 
and 70 from post-intervention who met inclusion criteria were reviewed in the pre-intervention 
group and 70 charts who met inclusion criteria were reviewed in the post-intervention group.  
Most patients screened for COPD were age 51+. The pre-implementation group 
represented age group was 61+ (49%) and for the post-implementation group it was ages 51-61 
(43%). The smallest groups for both pre and post was the 40-50 year old group (24% and 18.6% 
respectively). There were more female participants than male participants in the study. There 
was a statistically significant difference (p= .007) in the number of female participants in the pre 
(n=65, 65%) and post (n=30, 44.3%). The majority of patients for both pre and post were 
Caucasian (74% and 67.1% respectively). The most common symptom reported in patients in 
both the pre and post was a cough (52% and 42.9%).  Similarly, since most patients were 
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presenting with cough, provider documentation of ICD-10 codes of patients presenting 
symptoms were highest with cough (R05) in both the pre and post group (81% and 48.6%), 
which was statistically significant, (p=.001). See table 3 for demographic and clinical 
characteristics pre- and post-educational intervention.   
Provider Knowledge  
 Seven knowledge-based questions on COPD and the COPD-PS screening tool were 
analyzed in both the pre- and post-tests. Two questions evaluated provider knowledge on COPD-
PS screening tool and five questions tested provider knowledge on risk factors, prevalence, 
diagnostic testing, characteristics and symptoms of COPD.  Each question had only one correct 
answer and was coded accordingly with the score of any incorrect answer as 0 and the correct 
answer as 1.0, which created a range of 0-7. Both the pre- and post-tests were distributed via 
survey to the providers email using Qualtrics.  
 A comparison of means of each knowledge domain question pre-test versus post-test is 
presented in Table 5. There was an increase in mean knowledge (pre and post means, 
respectively) though it was not significant (p=.390). scores but there was not a statistically 
significant difference between the pre- and post-study scores, (p=.390). The overall mean score 
of provider knowledge increased from 6.75 out of a possible 7 correct answers (SD=0.50) before 
the intervention to 7 out of 7 correct (SD=0.00) after the intervention. See Table 4 and Figure 1 
Provider Attitudes  
A comparison of means of provider attitudes towards COPD screening and the COPD-PS 
screening tool questions for the pre-test versus post-test is presented in Table 4 and Figure 2. 
Provider attitude mean scores in the pre-test was 4.12 out of a possible 5 points (SD=0.75) 
compared to the post-test of 4.93 (SD=0.12) Although, the overall change between pre- and post-
tests mean scores for provider attitudes was not statistically significant.  
Provider Self-Efficacy 
A comparison of means of provider self-efficacy towards COPD screening and the 
COPD-PS screening tool questions for the pre-test versus post-test is presented in Table 4 and 
Figure 3. Provider self-efficacy mean scores in the pre-test was 4.12 out of a possible 5 points 
(SD=0.85) compared to the post-test of 5.00 (SD=0.00). Although, the overall change between 
pre- and post-tests mean scores for provider self-efficacy was not statistically significant 
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(p=0.133), is it worth noting that provider self-efficacy towards utilization of the COPD-PS 
screening tool and screening for COPD in the primary care improved..  
Provider Current Screening Practice  
Currently there is no standard screening process to identify patients for COPD in the 
primary care office at this organization. Providers were asked in the pre-and post-tests what 
methods they use to help facilitate screening for COPD. The providers scores were ranked from 
“Always (4) to Never (1)” on which tools they used to screen patients for COPD, both before and 
after the educational intervention. The method used most often to help aid in diagnosis of COPD 
in the pre-test was spirometry with a mean of 3.75 (SD=0.96) and in the post-test was surveys 
with a mean of 2.00 (SD=0.00), which was statistically significant (p=.003). The least used 
method in both pre-and post-test was chest x-ray 3.00 (SD=0.82) and 2.00 (SD=0.00) 
respectively). The method providers chose to screen patients for COPD in the primary care office 
was statistically significant in the use of surveys. (see Table 4 and Figure 4).  
Measurement of COPD-PS Screening Tool  
 Pre-Intervention 
The PI performed a chart review of 100 randomly selected patients who met all inclusion 
criteria and for whom screening was indicated during the pre-intervention months of June 
through August 2018. Of those 100 patients, zero patients were screened for COPD using the 
COPD-PS screening tool and no documentation elsewhere of COPD screening for any patient 
was found in patient’s charts. Although these patients were considered at risk for COPD, there 
was no documentation in patient’s EHR of screening for COPD using the COPD-PS screening 
tool, spirometry or other screening tools. This finding indicates that patients who were not 
screened for COPD but met inclusion criteria could have been screened and diagnosed for COPD 
earlier in the disease process if regularly screening for COPD occurred in the primary care 
setting (see Table 3 and Figure 4). 
Post- Intervention 
The primary investigator performed a chart review of 70 randomly selected patients who 
met all inclusion criteria and for whom screening was indicated during the post-intervention 
months of June through August 2019. Of those 70 patients, 16 (22.9%) had the COPD-PS 
screening tool performed and scanned into the Media tab in the patients EHR and 54 (77.1%) did 
not have the screening tool performed. Provider documentation of the COPD-PS screening tool 
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score was documented 14 times (20.0%) at the end of the patient’s assessment and plan in their 
office visit note. Provider documentation of COPD-PS may have not been recorded if provider 
did not see results of score, if paper copy was lost before being scanned into patient’s EHR or if 
patient did not score high enough to warrant provider discussion and spirometry referral. See 
Table 3 and Figure 4 for comparison of COPD-PS screenings performed and documented pre-
and post-intervention.  
A chi-square test was used to analyze COPD-PS screening rates for patients who met 
screening requirements in the pre-and post-intervention periods. Analysis revealed that there was 
significant statistical differences in the COPD-PS screening tool being performed (p=.001) and 
documentation (p=.001) of COPD-PS from the pre-to-post intervention periods (see Table 3). 
Increased Spirometry Screening Rates 
 Pre-Intervention 
The primary investigator performed a chart review of 100 randomly selected patients who 
met all inclusion criteria and for whom screening for COPD was indicated during the pre-
intervention months of June through August 2018. Of those 100 patients, two patients (2.0%) 
had spirometry ordered, while the other 98 patients (98.0%) did not. Reasons for not screening 
for COPD or ordering spirometry were not documented in the patient’s EHR. Reasoning for 
spirometry not being ordered could be correlated with providers not using the COPD-PS 
screening tool for at risk patients. Provider documentation and screening for patients using the 
COPD-PS screening tool could have identified patients at risk for COPD, which would have led 
diagnostic spirometry testing.  
Post-Intervention 
The primary investigator performed a chart review of 70 randomly selected patients who 
met all inclusion criteria and for whom screening was indicated during the post-intervention 
months of June through August 2019. Of those 70 patients, 14 (20.%) had spirometry ordered 
and 56 (80.0%) did not. Reasons for not ordering spirometry was documented in four of the 56 
patients charts, “patient COPD-PS score less than 5” from one provider. Of the 14 patients who 
had spirometry ordered, four patients did not follow through and get testing performed, two 
patients were hospitalized and spirometry testing was performed at the hospital and eight patients 
had spirometry performed. Of the eight patients who had spirometry orders placed during the 
post-intervention period, three patients’ spirometry readings were normal and five indicated 
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airway obstruction, indicating a diagnosis of COPD. Physicians performing spirometry on the 
patients include comments such as “spirometry demonstrates severe airway obstruction 
FEV1/FVC 51, FEV1 37% of predicted”; lung volumes are consistent with moderate restrictive 
and obstructive lung disease”; “moderate airway obstruction”; “moderate obstruction, 
recommend full PFT.” 
A chi-square analysis was used to analyze spirometry ordering rates for patients in the 
pre-and post-intervention periods. Analysis revealed that the difference in spirometry ordering 
rates from the pre- to post-intervention periods was statistically significant (p=.001). Patients 
that had spirometry ordered in the post-intervention were patients who had the COPD-PS 
screening tool completed. This finding is significant and supports the literature from Martinez, et 
al., 2008; Spyratos, Haidich, Chloros, Michaelopoulou, & Sichletidis, 2017 & Tsukuya, et al., 
2015, that utilization of the COPD-PS can identify at risk patients for COPD, who would benefit 
from diagnostic spirometry. Utilization of the COPD-PS screening tool was able to aid in 
diagnosing five pre-undiagnosed patients with COPD, which may not have occurred without the 
COPD-PS. See Table 3 and Figure 5 for comparison of order rates pre and post-intervention. 
Barriers and Facilitators Identified 
At the end of the provider pre-and post-implementation survey, providers were asked if 
they felt there were barriers for screening for COPD in their setting and what facilitators were 
available to assist them in overcoming these barriers. By allowing providers to leave comments, 
the PI hoped to gain insight on the providers’ perspective of barriers and identify potential 
solutions in order to increase screening rates for COPD.  
Three out of the four providers provided comments about the barriers they perceived and 
what facilitators may help overcome these barriers. Provider comments on perceived barriers 
include “easier access to spirometry”; “time to screen patients and time to do spirometry” and 
“improve pay models since I won’t get paid for taking extra time to do screen/test.” Facilitators 
to screening include “more time with patients’; ‘having nurses do screen and do spirometry” and 
“company have machine here and pay to compensate time spent.” One provider stated that 
“nursing staff could be beneficial in overcoming these barriers by completing and documenting 
the screening tool in the patients chart and performing the spirometry if it was warranted for the 
patient.”  
 




Patient Demographic and Clinical Characteristics 
 The findings from this study support findings from previous studies that the use of the 
COPD-PS screening tool is an effective way to identify patients at risk for COPD in the primary 
care setting. The findings in this study are similar to current studies in the literature (Martinez, et 
al., 2008; Spyratos, Haidich, Chloros, Michaelopoulou, & Sichletidis, 2017; Tsukuya, et al., 
2015 & Yawn, et al., 2014). The results of this study are comparable to other studies that have 
also found higher incidences of COPD in Caucasian adult patients ages 51 + (Martinez, et al., 
2008; Tsukuya, et al., 2015 & Yawn, et al., 2014). A study performed by Jenkins, et al., (2017) 
found that the prevalence of COPD is increasing more rapidly in woman than in men, which was 
also present in this study, (p= .007).  This finding indicates the need for providers to equally 
screen both men and women who present to the office with COPD symptoms. 
A study performed by Martinez, et al., (2008) used the COPD-PS screening tool to 
determine that patients who presented with symptoms of COPD (dyspnea, chronic cough, 
chronic sputum production, and a history of exposure to risk factors, such as smoking) and had a 
positive COPD-PS score were diagnosed with COPD after spirometry confirmation. This finding 
was also found in this study, which found five patients previously undiagnosed with COPD. 
Without utilization of the COPD-PS screening tool patients may have not been screened for 
COPD and referred for diagnostic spirometry to confirm a diagnosis of COPD.  
Influencing Provider Knowledge, Attitudes, Self-Efficacy  
A provider-based educational intervention improved provider, knowledge, attitudes and 
self-efficacy related to COPD screening and utilization of the COPD-PS screening tool in this 
study. There was not much variability in provider attitudes scores, since most providers agreed or 
strongly agreed with each statement in the pre/post survey. Though the overall means for 
provider knowledge, attitudes and self-efficacy increased from the pre- to post-implementation 
study, the change was not statistically significant. Provider knowledge, attitudes and self-efficacy 
was consistently positive and improved after education, indicating that providers are capable of 
identifying at risk patients for COPD as well as ordering spirometry for diagnostic testing.  
Provider knowledge scores from the pre and post-study indicate that providers are 
underestimating the problem of COPD. One of the four providers in the pre-implementation 
survey missed one of the seven knowledge question. The question the provider missed was the 
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number of patients who are undiagnosed with COPD in the United States . All four providers got 
all seven knowledge questions correct in the post-implementation study, indicating that they are 
knowledge about COPD and the availability and process of screening for COPD using the tool.  
With an estimated 24 million Americans undiagnosed with COPD, it is essential for providers to 
screen patients for COPD (CDC, 2018). Although there are screening tools to aid in diagnosing 
COPD, providers may choose not to use one based on their personal instinct and assumptions of 
correctly identifying and diagnosing patients for COPD without a screening tool or diagnostic 
spirometry. By speculating a diagnosis of COPD but not testing for it, patients may remain 
undiagnosed with COPD or be diagnosed at a later stage in life. Therefore, a standardized 
screening tool is needed to accurately diagnose patients at the earliest sign of a possible COPD 
diagnosis.  
Influencing Provider Spirometry Screening Rates 
Provider screening rates for COPD utilizing the COPD-PS was statistically significant  
from the pre to post-implementation phase. Prior to the educational intervention providers were 
not using any form of screening tool to assess patients for COPD, therefore it is likely that the 
increased screening rates of COPD was due to provider education. Without performing a COPD 
screen on patients, five patients would still be undiagnosed with COPD. Providers that used the 
COPD-PS screening tool and received a positive score (5 or greater) placed a referral for 
spirometry. Of the 14 referrals, five patients with previously undiagnosed COPD were 
appropriately diagnosed with COPD and started on medications and three had normal spirometry 
results indicating no obstruction or diagnosis of COPD. There were an additional four patients 
that had the order in for spirometry but did not go.  
Four patients that completed the COPD-PS screen scored less than five, which was not 
appropriate for spirometry referral. It would be of interest to see if patients who scored less than 
five were screened again in the winter months when symptoms are more apparent. The last two 
patients who had referrals for spirometry were hospitalized before spirometry was performed but 
had spirometry performed during their hospital admission.   
By offering in-office spirometry providers would not have to refer patients out for 
screening, could ensure screening was performed during the office and could bill for the service 
and interpretation of results. Nursing staff is essential to the success of COPD screening and in-
office spirometry. Nursing staff could screen patients for COPD as well as perform spirometry 
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on patients that meet screening requirements, which could decrease providers perceived barrier 
of limited time with patients and limited provider’s time. A study performed by Ruppel, Carlin, 
Hart, & Doherty (2018), found that a  formal questionnaire, such as the COP-PS can improve the 
efficacy and accuracy of a COPD diagnosis when used to select patients for diagnostic 
spirometry. Similarly, Mapel, Dalal, Johnson, Becker, & Hunter (2015), reported that COPD 
disease severity was underestimated in about 40% of subjects before spirometry and that 
treatment changes occurred in 37% of cases when the primary care practitioner had spirometry 
results. These findings are important for future studies, since they highlight the importance of 
screening at risk patients for COPD could lead to a diagnosis of COPD that could have been 
underdiagnosed in the past. In this study, there was a significant improvement in provider 
screening for COPD utilizing the COPD-PS screening tool, documentation and spirometry 
ordering following a positive COPD-PS score between the pre and post implementation phase.  
Barriers to COPD Screening 
 During the chart review “lack of transportation” was cited for one of the four patient as 
the reason for why spirometry testing was not completed. The other three referrals for spirometry 
were open but the patient’s never went for testing. A study performed by Yawn, Wollan, Textor, 
& Yawn (2016) reported provider perceptions of barriers for screening for COPD, which was 
consistent with findings in Han, et al (2015) and Dirven, et al’s., (2013) studies that listed “lack 
of easy access to spirometry,” time limitation,” lack of expertise to interpret results of 
spirometry,” “lack of reimbursement,” and “lack of nursing staff” as barriers to in-office 
spirometry. Likewise, Enocson, et al., (2018) performed a study that examined patient 
perceptions on barriers for COPD screening. Participants suggested that screening activities for 
COPD should take place in a convenient place, such as their general practice, as it is “close to 
home and travel costs are minimal” (Enocson, et al., 2018). Enocson, et al., (2018) reported 
additional patient barriers to COPD screening which were, “too busy,” depends on how long test 
would take because I take care of my disabled wife,” “takes 3 months to see PCP for follow-up,” 
and “limited time to be off work.” Similarly, both providers and patients have similar barriers to 
COPD screening and diagnostic spirometry to confirm COPD in the primary care setting. 
Availability of in-office spirometry has led to increased use of spirometry and confirmation of a 
diagnosis of COPD in the primary care setting. In a study by Yawn, et al., availability of in-
office spirometry confirmed diagnosis of COPD in more than 58.2% of the patients with a 
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positive COPD-PS score (2015). Likewise, Murphy, et al., (2016) found 29% of patient who had 
in-office spirometry performed, 69% were diagnosed with COPD. These findings are similar to 
this study, as they are patients who were previously undiagnosed with COPD, were diagnosed 
after spirometry confirmation.  
The significance of this finding is that there is not only a need for early COPD screening 
but there is also a need for availability of in-office spirometry. Identification of patient barriers to 
spirometry was not asked of patients, however, in-office spirometry could save patients time, 
decrease transportation and prevent an additional co-pay (Martinez, et al., 2008; Yawn, et al., 
2014). It would be interesting, however, to perform this same study again but with availability of 
in-office spirometry and all providers and nursing staff to receive the educational session. 
Implications for Future Study  
 Providers who offered their written feedback in the pre- and post-intervention survey 
allowed for identification of barriers and possible solutions to increase COPD screening in the 
primary care setting. One way that providers could improve patient care is by screening patients 
for COPD and having spirometry on site in the primary care office.  The study by Yawn, et al., 
(2014), revealed a strong association between office-based spirometry and a significant increase 
in COPD diagnosis in primary care providers (p=.002). Availability of spirometry in the office 
would be beneficial for patients as well as providers. Patients may be more likely to follow 
through with testing if it is offered at the same time of their office visit.  
Another recommendation for future practice includes the use of a screening tab for 
COPD in the organizations computer system. Currently there is no established screening tool in 
the Epic computer system that is utilized by the study site to help providers remember to screen 
patients for COPD. The COPD-PS screening tool is currently the only evidence-based screening 
tool developed to aid in early diagnosis of patients with COPD (Martinez, et al., 2008).  
Integration of the COPD-PS screening tool in patients EHR can eliminate nursing from having 
patients to complete the paper form and then scan it into each patients EHR. This step will allow 
providers to know which patients have been screened and will allow providers to be able to order 
diagnostic testing and address results with patients easier. Integration of the screening tool in a 
computer system will allow for patient information to be safely kept in the patient’s own EHR, 
thus eliminating potential patient privacy issues and loss of paper screening forms. Performing 
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screening tool in the computer would be instant and would not require for nursing staff to have to 
scan documents into the computer system, which would save time and protect patient privacy. 
Another recommendation for future practice includes the use of educating nursing staff to 
screen at risk patients for COPD and perform spirometry in the office. All providers listed nurses 
as facilitators in overcoming barriers for screening patients for COPD. Utilizing nursing staff 
could potentially increase the number of patients being screened for COPD, increase availability 
of spirometry testing for those patients with limited transportation and increase provider billing. 
It is worthwhile to note the potential impact of provider-based interventions on certain 
outcome measures. Since there was a statistically significant change in provider use and 
documentation of the COPD-PS as well as spirometry order rates, it may be beneficial to conduct 
another educational session for all providers and their nurses to attend. This finding is significant 
because it showcases that screening for COPD using the COPD-PS and provider referral for 
spirometry to diagnosis COPD is significant in identifying previously undiagnosed patients with 
COPD  There would be two educational sessions, one for the nursing staff and one for the 
providers. Education would be provided to both on who to screen, how to document and what to 
do with a positive COPD-PS score. Handouts would be given to providers and nursing staff to 
review patient inclusion and exclusion criteria. With more providers and nursing staff screening 
patients for COPD, more patients would be diagnosed at an earlier stage of the disease progress, 
this leading to better patient outcomes.  
Limitations 
 Limitations for this study include a small sample size of providers (n=4) at one primary 
care office with mostly Caucasian participants. Provider knowledge, attitudes, self-efficacy and 
screening practice was limited with the size of participants and only being conducted at one 
office. A larger sample size with more offices would have allowed for variances in pre-post 
interventions sample data. Additional risk factors such as family history of COPD, childhood 
respiratory infections, congenital/developmental abnormalities, occupational dusts, vapors, 
fumes, gases and other chemicals could be useful for inclusion criteria in future studies.  
The timeframe for implementation was short (three months) and took place during the summer 
months, when COPD symptoms are not as prominent. Performing the study over 6 months and 
starting from October to March could be more beneficial in screening patients for COPD, since 
that is when exacerbations are most common. The reliability and validity of the pre- and post- 
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test has not been determined, as it was generated by the PI and not trialed prior to this study.  
Data collected from providers in the pre-and post-test may also involve bias opinions to the need 
for COPD screening in the primary care office.  
Recommendations 
Although this study did not show any statistical significant findings with provider 
knowledge, attitudes and self-efficacy with COPD screening, the need to determine the reliability 
and validity of the provider survey accessing these components is one important implication for 
further study, as the true reliability and validity remains unknown. If reliability and validity 
cannot be achieved, consideration of a different validated survey may be warranted for future 
studies. It may also be beneficial to extend the time frame of the study to determine whether 
knowledge, attitudes, and self-efficacy were sustained over time or became more relevant during 
the winter months when COPD exacerbations are more prominent. Lastly, implementation of this 
study in a multi-site office would be ideal to test replicability and generalizability of the study.  
Conclusion  
COPD is the fourth most common cause of mortality and disability in the US, with higher 
incidences in Kentucky than majority of other states (Croft, et al., 2018). Although there is no 
cure for COPD, earlier screening and detection can improve short-and long-term patient 
outcomes, increase quality of life, decrease co-morbidity and mortality, and reduce costs related 
to underdiagnosed COPD.  
Utilization of a screening tool, such as the COPD-PS, could be instrumental in early 
identification and diagnosis of patients with COPD in the primary care setting. In this study a 
pre- and posttest revealed an overall increase in provider knowledge, attitudes and self-efficacy 
with utilization of the COPD-PS screening tool and COPD, however differences between these 
findings in the pre and posttest were not statistically significant. Pre and post-tests revealed an 
increase in provider documentation, screening for COPD using the COPD-PS screening tool and 
order referrals for spirometry, which was statically significant. It is important to note the 
significance of the barriers and facilitators providers noted for screening for COPD for future 
practice. Future propositions for practice change may involve implementing a documentation tab 
for COPD screening in the Epic computer system to help providers remember to screen patients, 
order spirometry and review results with patients. Future initiatives for COPD screening using 
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the COPD-PS screening tool and availability of in-office spirometry could increase earlier 






























COPD SCREENING RATES 
29 
 




+ + + + =
#1 #2 #3 #4 #5
1. During the past 4 weeks, how much of the time did you feel short of breath?
2. Do you ever cough up any “stuff,’’ such as mucus or phlegm?
4. Have you smoked at least 100 cigarettes in your ENTIRE LIFE?
5. How old are you?
3. Please select the answer that best describes you in the past 12 months. 
I do less than I used to because of my breathing problems.
If your total score is 5 or more, your breathing problems may be caused by chronic obstructive pulmonary disease 
(COPD). COPD is often referred to as chronic bronchitis and /or emphysema and is a serious lung disease that slowly
gets worse over time. While COPD cannot be cured, it is treatable.
Please share the completed survey with your doctor. The higher your score, the more likely you are to have COPD. 
Your doctor can help evaluate your breathing problems by performing a simple breathing test, also known 
as spirometry.
If your total score is between 0 and 4, and you experience problems with your breathing, please share this survey 
with your doctor. Your doctor can help evaluate any type of breathing problem.
How to score the survey: In the spaces below, write the number that is next to your answer for each of the 
questions. Add the numbers to get the total score. The total score can range from 0 to 10.
COPD Population Screener is a trademark of QualityMetric Incorporated.
















This survey asks questions about you, your breathing and what you are able to do.
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How to Score Your Screener: In the spaces below, write the number that is next to your answer for each of the questions.  
Add the number to get the total score. The total score can range from 0 to 10.
            +           +           +           +           =                                    
    (#1)      (#2)      (#3)      (#4)          (#5)            TOTAL SCORE
If your total score is 5 or more, this means your breathing problems may be caused by chronic obstructive pulmonary disease (COPD). The 
higher your score, the more likely you are to have COPD. COPD is often referred to as chronic bronchitis and/or emphysema and is a serious lung 
disease that slowly gets worse over time. While COPD cannot be cured, it is treatable, so please share your answers to the five question screener 
with your healthcare professional (HCP).
If your total score is between 0 and 4, and you are experiencing problems with your breathing, please share your answers to the five-question 
screener with your HCP. 
Only your HCP can decide if you have COPD. Your HCP can hel  evaluate your breathing problems by performing a breathing test, also known as 
spirometry. Don’t wait. Call your HCP today to make an appointment to see if you may be at risk for COPD. Remember, when speaking to your HCP, 
be honest and open in describing your symptoms and explain how your breathing problems affect your activity level on a daily basis.
This survey asks questions about you, your breathing and what you are able to do. To complete 
the survey, mark an X in the box that best describes your answer for each question below.
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Appendix B. Provider Pre-Post Implementation Test Survey 
Start of Block: COPD Screening Survey 
Your answers are anonymous. In order to match your pre-test and post-test, please select a random number with 3 or 
more digits. Remember this digit and copy it onto the post-test 
Number:________________________________________________________________ 
 
What is your gender 
o  Male  (1)  
o  Female  (2)  
 
What is your degree 
o  NP  (1)  
o  MD  (2)  
 
Years of experience 
o  Less than 5 years  (1)  
o  More than 5 years  (2)  
 
Q1 About how many patients are underdiagnosed with COPD in the United States? 
o  32 million  (1)  
o  17 million  (2)  
o  12 million  (3)  
o  24 million  (4)  
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Q2 At what age should screening for COPD be started? 
o  40  (2)  
o  55  (3)  
o  60  (4)  
o  65  (5)  
 
Q3 What is the main risk factor for COPD? 
o  Air Pollution  (1)  
o  Biomass Fuel Exposure  (2)  
o  Asthma  (3)  
o  Smoking  (4)  
 
Q4 What symptom is not characteristic of COPD? 
o  Chronic Cough  (1)  
o  Bradycardia  (2)  
o  Dyspnea  (3)  
o  Productive Sputum  (4)  
 
Q5 What test is required by GOLD guidelines to establish a diagnosis of COPD? 
o  Chest X-Ray  (1)  
o  Patient history  (2)  
o  Family history  (3)  
o  Spirometry  (4)  
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Q6 How many questions is the COPD-PS? 
o  4  (1)  
o  5  (2)  
o  6  (3)  
o  7  (4)  
 
Q7 What score on the COPD-PS screening tool is considered "high risk" for diagnosis of COPD and warrants 
further testing? 
o  0-4  (1)  
o  5-10  (2)  
o  10-20  (3)  
 
Q8 What is your current practice for screening for COPD in the primary care setting? Do you use: 
 Always (4) Sometimes (3) Rarely (2) Never (1) 
Chest X-Ray (1)  o   o   o   o   
Screening Tools (2)  o   o   o   o   
Spirometry (3)  o   o   o   o   
Surveys (4)  o   o   o   o   
Other (5)  o   o   o   o   
 
Q9 Do you currently use any screening tools to help identify patients with COPD? 
o  Yes  (1)  
o  No  (2)  
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Q10 If yes, do you use 
o  COPD Population Screener (COPD-PS)  (1)  
o  COPD Assessment Test (CAT)  (2)  
o  Chronic Respiratory Questionnaire (CCQ)  (3)  
o  Modified Medical Research Council (mMRC)  (4)  
 
Q11 Do you feel there are barriers in screening patients for COPD in your setting? 
o  Yes  (1)  
o  No  (2)  
 









Q14 On a scale from Strongly agree to Strongly disagree, record your responses to screening for COPD using the 
COPD-PS screening tool 







































I feel screening 
for COPD is 
important in the 
primary care 
setting (1)  
o   o   o   o   o   
I understand 
which patients 
are at risk for 
COPD (2)  
o   o   o   o   o   
Screening for 
COPD using the 
COPD-PS can 
earlier identify 
patients at risk 
for COPD (3)  
o   o   o   o   o   
I understand 
how to use the 
COPD-PS (4)  




for COPD using 
the COPD-PS 
(5)  
o   o   o   o   o   
The COPD-PS 
screening tool is 
easy to use (6)  





patients I screen 
for COPD (7)  
o   o   o   o   o   
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Appendix C. Provider Email Consent 
 
Dear Providers at NCMA-Dixie, 
 
You are being invited to participate in a research study, “The Effect of Educating Providers on How to Implement 
the COPD-PS tool on Screening Rates in the Primary Care Setting.” The purpose of this study will be to assess 
baseline practice related to screening for Chronic Obstructive Pulmonary Disease (COPD) among adult patients at 
in one primary care setting. Furthermore, the purpose will be to educate providers about COPD and the COPD-PS 
screening tool and to evaluate subsequent changes in knowledge and screening rates. 
 
The Principal Investigator is Kelli Craig a faculty member in the Doctor of Nursing Practice Program at the 
University of  Kentucky College of Nursing and current employ at Norton Healthcare.   
  
If you agree to participate in the study, you will be asked to complete an online survey on Qualtrics that asks you to 
provide answers to several question items, in the form of multiple score,  Likert Scale and fill-in the blank. There is 
no risk to participation in the study, other than participants might remember a negative experience when completing 
the survey instrument.   
  
The benefits that may be derived from this research include that with future improvement of COPD screening, 
individuals who have not been previously recognized or screened for COPD will be identified as screening process 
improvement takes place.  
 
Your participation in this study is entirely voluntary. We hope to receive 11 completed questionnaires so your 
answers are important to us.  Of course, you have a choice about whether or not to complete the 
survey/questionnaire, but if you do participate, you are free to skip any questions or discontinue at any time.  The 
survey will take about 3 minutes to complete.   
   
We make every effort to safeguard your data once received on our servers via Qualtrics.  Given the nature of online 
surveys, as with anything involving the internet, we can never guarantee the confidentiality of data still en route to 
us. Qualtrics is a secure, web-based application designed exclusively to support data capture for research studies.    
Your responses will be anonymous. Records of your participation in this study will be kept confidential to the extent 
permitted by law. Results of this research will be reported as summarized data and will not contain any identifiable 
individual data. For this study, survey respondents will not be ask to provide a name, email address or any 
identifying information.  
 
Should you have any questions you may contact Kelli Case Craig, the Principal Investigator, at kaca268@uky.edu 
or per telephone at (812) 987-9557. If you have complaints, suggestions, or questions about your rights as a research 
volunteer, contact the staff in the University of Kentucky Office of Research Integrity at 859-257-9428 or toll-free 
at 1-866-400-9428.  
  
Your completion of the survey will be considered your consent to participate in the study and as your agreement 
that you have been sufficiently informed of the purpose of the study and any risks and benefits. If you agree to 
participate in the study please click on the below link to access the survey.  
  
SURVEY LINK WILL BE COPIED HERE  
  




Kelli Case Craig 
College of Nursing, University of Kentucky  
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Appendix D. Patient Survey Cover Letter 
 
To Patients of NCMA- Dixie  
 
Researchers at the University of Kentucky are inviting you to take part in the CODP-PS questionnaire about risk for 
development of COPD in the greater Louisville area. You are receiving this survey because you are being seen for a 
routine physical in which health maintenance data, such as diet, exercise, and preventative screenings, such as the 
COPD-PS are going to be discussed.  
 
Although you may not get personal benefit from taking part in this research study, your responses may help us 
understand more about properly screening for COPD. Some volunteers experience satisfaction from knowing they 
have contributed to research that may possibly benefit others in the future.  
 
If you do not want to participate, simply do not fill out the five-question survey on the back of this form.  
 
The questionnaire will take about 2 minutes to complete. Participants are asked to complete the survey while in the 
provider office.  
 
Your response to the survey is anonymous which means no names will appear or be used on research documents, or 
be used in presentations or publications. The research team will not know that any information you provided came 
from you, nor even whether you participated in the study.  
Your information collected for this study will NOT be used or shared for future research studies, even if we remove 
the identifiable information like your name, clinical record number, or date of birth.  
 
There are no risks to participating in this study.  
 
We hope to receive completed questionnaires from about 250 people, so your answers are important to us. Of 
course, you have a choice about whether or not to complete the survey/questionnaire, but if you do participate, you 
are free to skip any questions or discontinue at any time. While filling out the survey, if you experience any anxiety 
related to the questions being asked, you can skip the questions and consult with your provider. We understand that 
these questions could potentially lead to feelings of anxiety about the possibility of a diagnosis of COPD, therefore it 
is important to discuss with your provider your risks for COPD. 
 
If you have questions about the study, please feel free to ask; my contact information is given below. If you have 
complaints, suggestions, or questions about your rights as a research volunteer, contact the staff in the University of 
Kentucky Office of Research Integrity at 859-257-9428 or toll-free at 1-866-400-9428.  
 
If you have any questions about the study or need to speak with my faculty advisor, Elizabeth Tovar, PhD, APRN; 
her contact information is (859) 323-6611 or email egres2@uky.edu.  
 
By filling out the questionnaire on the back of this consent, you consent to being a part of this study.  
 
Thank you in advance for your assistance with this important project.  
Sincerely,  
Kelli Case Craig  
College of Nursing- Graduate Studies, University of Kentucky  
PHONE: 812-987-9557  
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Pre and Post Nominal Electronic 
Health Record 
ICD 10 Codes Dyspnea=1 
Cough=2 
Sputum=3 


































1-7 based on # 
correct 
Pre and Post Scale Survey 
Attitudes  about 
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Likert Scale Pre and Post Scale Survey 
Self-efficacy 
about COPD-PS 
Likert Scale Pre and Post Scale Survey 
Current Practice 
COPD screening  







Timeline Data Source 
Gender Male vs Female Pre and Post Baseline Nominal 
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Experience < 5 years vs >5 
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Table 2.  Summary of Provider Demographics 




Surveys Completed 4 67% 
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Table 3. Statistical Analysis of Demographic and Clinical Characteristics Pre- and Post-
Educational Intervention (N =170) 
 
 Pre-intervention 
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   African American 
   Caucasian 
   Hispanic 














   Dyspnea 
   Cough 
   Sputum 
   Dyspnea/Cough 
Dyspnea/Cough/Sputum 
   Cough/Sputum 
ICD 10 Codes 
   Dyspnea 
   Cough 
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Knowledge 0-7 6.75 (0.50) 7.00 (0.00) .391 
Provider Attitudes 5-25 4.12 (0.75) 4.93 (0.12) .090 
Provider Self-Efficacy 5-25 4.12 (0.85) 5.00 (0.00) .133 
Current Practice for 
COPD Screening 
 
   Chest X-ray 
   Screening Tools 
   Spirometry 
   Surveys 
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Q1 - About how many patients are underdiagnosed 
with COPD in the United States? 
 
3.25 4.00 




Q3 - What is the main risk factor for COPD? 
 
4.00 4.00 
Q4 - What symptom is not characteristic of COPD? 
 
4.00 4.00 
Q5 - What test is required by GOLD guidelines to 
establish a diagnosis of COPD? 
 
4.00 4.00 
Q6 - How many questions is the COPD-PS? 
 
4.00 4.00 
Q7 - What score on the COPD-PS screening tool is 
considered "high risk" for diagnosis of COPD and 
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About  how  many  patients  are  underdiagnosed  with  COPD  in
the  United  States
At  what  age  should  screening  for  COPD  be  started
What  is  the  main  risk  factor  for  COPD
What  symptom  is  not  characteristic  of  COPD
What  test  is  required  by  GOLD  guidelines  to  establish  a
diagnosis  of  COPD
How  many  questions  is  the  COPD-­‐PS
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0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
I  feel  screening  for      COPD  is  important  in    the  primary  care
setting
Screening  for  COPD  using  the  COPD-­‐PS  can  earlier  identify
patients  at  risk  for  COPD
The  COPD-­‐PS  screening  tool  is  easy  to  use
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0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
I  understand  which  patients  are  at  risk  for  COPD
I  understand  how  to  use  the  COPD-­‐PS
I  am  comfortable  with  screening  for  COPD  using  the  COPD-­‐PS
Provider  Self-­‐Efficacy
Post-­‐Intervention Pre-­‐Intervention
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Provider  Current  Practice  for  COPD  Screening
Post-­‐Intervention Pre-­‐Intervention
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Number  of  COPD-­‐PS  Screening  Tools  Performed
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